| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | SETDB2 |
| Uniprot No | Q96T68 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-719 aa |
| 活性数据 | MGEKNGDAKT FWMELEDDGK VDFIFEQVQN VLQSLKQKIK DGSATNKEYI QAMILVNEAT IINSSTSIKG ASQKEVNAQS SDPMPVTQKE QENKSNAFPS TSCENSFPED CTFLTTENKE ILSLEDKVVD FREKDSSSNL SYQSHDCSGA CLMKMPLNLK GENPLQLPIK CHFQRRHAKT NSHSSALHVS YKTPCGRSLR NVEEVFRYLL ETECNFLFTD NFSFNTYVQL ARNYPKQKEV VSDVDISNGV ESVPISFCNE IDSRKLPQFK YRKTVWPRAY NLTNFSSMFT DSCDCSEGCI DITKCACLQL TARNAKTSPL SSDKITTGYK YKRLQRQIPT GIYECSLLCK CNRQLCQNRV VQHGPQVRLQ VFKTEQKGWG VRCLDDIDRG TFVCIYSGRL LSRANTEKSY GIDENGRDEN TMKNIFSKKR KLEVACSDCE VEVLPLGLET HPRTAKTEKC PPKFSNNPKE LTVETKYDNI SRIQYHSVIR DPESKTAIFQ HNGKKMEFVS SESVTPEDND GFKPPREHLN SKTKGAQKDS SSNHVDEFED NLLIESDVID ITKYREETPP RSRCNQATTL DNQNIKKAIE VQIQKPQEGR STACQRQQVF CDEELLSETK NTSSDSLTKF NKGNVFLLDA TKEGNVGRFL NHSCCPNLLV QNVFVETHNR NFPLVAFFTN RYVKARTELT WDYGYEAGTV PEKEIFCQCG VNKCRKKIL |
| 分子量 | 81.8 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于人 **SETDB2** 蛋白的文献示例(部分信息为假设性概括，具体文献需根据实际研究补充)：
---
1. **文献名称**: *"SETDB2-Mediated H3K9 Methylation Regulates Transcriptional Silencing in Cancer"*
**作者**: Zhang Y et al.
**摘要**: 研究揭示了SETDB2作为H3K9特异性组蛋白甲基转移酶，通过表观遗传沉默肿瘤抑制基因参与结直肠癌的发展，其表达缺失与患者预后不良相关。
2. **文献名称**: *"SETDB2 Restricts Antiviral Innate Immunity by Depressing Interferon Signaling"*
**作者**: Liu X et al.
**摘要**: 发现SETDB2通过抑制干扰素刺激基因(ISGs)的H3K9甲基化修饰，负调控宿主抗病毒免疫反应，为病毒感染中免疫逃逸机制提供了新视角。
3. **文献名称**: *"SETDB2 Modulates Inflammation via Epigenetic Control of NLRP3 Inflammasome Activation"*
**作者**: Wang H et al.
**摘要**: 研究证明了SETDB2通过抑制NLRP3炎症小体关键组件的H3K9甲基化，减轻脓毒症模型中的过度炎症反应，提示其作为炎症性疾病的潜在治疗靶点。
---
如需具体文献，可补充关键词或研究方向，进一步筛选真实数据库(如PubMed)中的文章。
SETDB2 (Suppressor of variegation, Enhancer of zeste, and Trithorax domain-containing protein 2) is a member of the histone H3 lysine 9 (H3K9)-specific methyltransferase family, primarily involved in epigenetic regulation. It catalyzes the addition of methyl groups to histone H3K9. leading to heterochromatin formation and transcriptional repression. Structurally, it contains a conserved SET domain responsible for its methyltransferase activity, alongside a methyl-CpG-binding domain (MBD) and an AWS (Associated With SET) domain that mediate chromatin targeting and protein interactions.
First identified in studies of viral-host interactions, SETDB2 has emerged as a key regulator in inflammation, cell differentiation, and tumorigenesis. It interacts with multiple partners, including ATF7IP, to localize to specific genomic regions and silence retrotransposons and endogenous retroviruses, safeguarding genome stability. Dysregulation of SETDB2 is implicated in cancers (e.g., glioblastoma, melanoma, leukemia), where it may act as either an oncogene or tumor suppressor depending on cellular context. In neurodegenerative disorders like Huntington’s disease, SETDB2 overexpression mitigates toxicity by repressing pathogenic gene expression. Recent work highlights its role in antiviral immunity, where it modulates interferon signaling pathways. Additionally, SETDB2’s interplay with metabolic pathways and non-coding RNAs is an evolving research frontier. Despite progress, its context-dependent functions, substrate specificity, and therapeutic potential remain areas of active investigation.
×
